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ABSTRACT
The most commonly sexually transmitted bacteria are Neisseria gonorrhoeae and Chlamydia tracho.
matis. The quinolones ofloxacin and ciprofloxacin have been shown to have activity against both of
these bacteria in vitro and in vivo. Ofloxacin is particularly well suited for the treatment of N.
gonorrhoeae and C. trachomatis cervical infection, which can be considered the earliest manifestation
of pelvic inflammatory disease (PID). Not only can ofloxacin be effectively used as a single agent, it
is also useful in treating urinary tract infections caused by Enterobacteriaceae. Although it has
moderate activity against anaerobes in general, ofloxacin does have activity against the anaerobes
commonly isolated from female patients with soft tissue pelvic infections. Thus, ofloxacin has the
potential for being utilized to treat early salpingitis. (C) 1993 Wiley-Liss, Inc.
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Ieisseria gonorrhoeae and Chlamydia trachomatis
are the two most common sexually transmitted
bacteria. They are responsible for the majority of
diseases involving the female reproductive tract that
can result in devastating sequelae. The spectrum of
diseases secondary to infection with either or both
of these bacteria encompasses relatively simple in-
fections such as urethritis and cervicitis and more
complex infections such as Bartholin’s gland and
Skene’s gland abscesses, endometritis, salpingitis,
disseminated gonococcal disease, and gonococcal ar-
thritis.
-6 Infection of the upper genital tract can
and often does result in infertility. Even if the
patient is able to achieve pregnancy, she is at con-
siderable risk for the development of an ectopic
pregnancy.
7-1 In addition, an individual who has
had salpingitis is often left with pelvic adhesions
and chronic pelvic pain or develops a pyosalpinx
that can result in a hydrosalpinx or tubo-ovarian
abscess. 7’1-13 Such an individual must often un-
dergo a hysterectomy with removal of her ovaries,
requiring subsequent hormonal replacement.
Therefore, the best defense against the patient’s
developing advanced disease is early recognition of
the initial infection along with appropriate treat-
ment and follow-up management.
Early gonococcal infection, i.e., urethritis and
cervicitis, is currently treated with ceftriaxone
(Rocephin, Roche Laboratories, Nutley, NJ), 150
mg IM, followed by doxycycline, 100 mg orally
twice daily for 7 days, to eradicate any chlamydial
infection. This treatment regimen, recommended
by the Centers for Disease Control (CDC),
4 is a
logical one because these two bacteria commonly
coinfect individuals. Of women with gonococcal
cervicitis, approximately 26% will be coinfected
with C. trachomat#.
15 Since most patients are
treated prior to receipt of the culture results, it is
important that antibiotic therapy be effective against
both N. gonorrhoeae (including penicillinase-pro-
Address correspondence/reprint requests to Dr. Sebastian Faro, Department of Gynecology and Obstetrics, The University
ofKansas School ofMedicine, 3901 Rainbow Blvd., Kansas City, KS 66160-7316.
Review Article
Received August 18, 1993
Accepted August 19, 1993QU1NOLONE TREATMENT OF GONORRHEA AND CHLAMYDIA FARO
TABLE I. Risk factors for sexually
transmitted disease
15 to 25 years of age (age group most vulnerable)
Use of oral contraceptives
Presence of an IUD
Multiple sex partners
Exposure to an individual with an STD
Presence of an STD
History of an STD
History of PID
ducing strains) and C. trachomatis. In addition,
patients seen in sexually transmitted disease (STD)
clinics and emergency rooms are not usually com-
pliant in their treatment regimen. If they are not
treated at the time of their initial examination but
are asked to return for the administration of appro-
priate treatment when the laboratory data are
known, they are not likely to return. On the other
hand, the administration of two antibiotics, one
injectable and one oral, is costly and time consum-
ing. Therefore, an effective single antibiotic agent
for the treatment of both infections would be less
costly, more effective, and more convenient.
PATIENT EVALUATION
Appropriate treatment of the patient with an STD
begins with an understanding of the profile of the
individual at risk. The first indication that an indi-
vidual may be harboring N. gonorrhoeae or C. tra-
chomatis is the presence of another sexually trans-
mitted organism such as Trichomonas vaginalis,
herpes virus, or the human papillomavirus. Demo-
graphic characteristics of patients at risk for acquir-
ing an STD are given in Table 1. A detailed sexual
history is important in treating the sexually active
patient. Germane to the treatment and follow-up of
such a patient is determining whether specimens
for the culture ofN. gonorrhoeae and C. trachomatis
should also be obtained from the oropharynx and
rectum. The clinician should also ascertain whether
the patient or her sexual partner has multiple part-
ners. Questions should be asked with regard to the
presence of genital lesions, past or present, and the
existence of lower abdominal pain, no matter how
mild or vague. The patient should be further que-
ried regarding the use of OCPs and any abnormal
vaginal bleeding, i.e., irregular menstrual bleed-
ing, breakthrough bleeding, or postcoital bleed-
ing.






The evaluation begins with a physical examina-
tion, reserving the pelvic assessment until last. The
pelvic examination should include a thorough as-
sessment of the external genitalia with retraction of
the clitoral hood and inspection between the crural
folds. A colposcopic examination will facilitate the
detection of vulvar lesions. The labia should be
thoroughly painted with 5% acetic acid to highlight
abnormal tissue and discern acetowhite epithelium.
If an ulcerative lesion is found, it should be evalu-
ated for the STDs listed in Table 2.
Ulcerative lesions may or may not be differenti-
ated on physical examination. The chancre of syph-
ilis is typically a clean-appearing, painless lesion,
whereas the lesions of the other bacterial STDs are
painful, with ragged borders, and have an overall
"dirty" appearance. Herpetic ulcers vary in size
from pinpoint lesions to large, crater-like ulcers
and are typically very painful. Appropriate speci-
mens should be obtained for Gram stain, Giemsa
stain, dark-field examination, and culture. The lab-
oratory should be consulted for the precise method
for obtaining, transporting, and labeling the speci-
mens. In this way, the specimens will be processed
appropriately for retrieval of the desired organ-
isms.
The vestibule of the vagina should be inspected
for the presence of a purulent discharge. The ure-
thra and Skene’s and Bartholin’s glands should be
palpated to determine if a purulent exudate is
present. If an exudate is present, a specimen should
be obtained for Gram stain and culture for the
isolation of N. gonorrhoeae, C. trachomatis, Myco-
plasma hominis, and Ureaplasma urealyticum. Again,
the entire genitalia should be examined for ulcer-
ative or abnormal growths. A biopsy specimen
should be taken of any lesion that is suspicious for
malignancy.
The vagina should be inspected for the charac-
teristics of any discharge: color, consistency, pH,
and odor. A healthy vaginal discharge has a pH of
3.8 to 4.2. A pI-I value between 4.2 and 4.5 may
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indicate an abnormality, whereas a pI--I > 4.5 defi-
nitely indicates an abnormal vaginal microflora.
Lower hydrogen ion concentrations (pH > 4.5)
indicate the presence of high counts of anaerobic
bacteria or T. vaginalis.
The evaluation of the cervix begins with an as-
sessment of the endocervical tissue: is it hyper-
trophic, erythematous, necrotic, or ulcerated? Is an
endocervical mucopurulent discharge present? It
should also be noted whether the cervix bleeds
briskly when gently touched with a cotton-tipped
applicator. The aforementioned characteristics are
all indications that an infection may be present. An
endocervical specimen should be obtained with a
Dacron-tipped applicator with a plastic or metal
shaft. Cultures should be obtained for C. tracho-
matis and N. gonorrhoeae. A Gram stain of the
endocervical discharge is helpful. If the specimen
does not reveal the presence of squamous epithelial
cells, Candida albicans, or T. vaginalis, it can be
considered a valid specimen not containing a vagi-
nal discharge. WBCs with gram-negative diplo-
cocci may indicate N. gonorrhoeae. However, if
there are WBCs but no gram-stainable bacteria, a
tentative diagnosis of C. trachomatis infection can
be made, although an M. hominis or U. urealyticum
infection cannot be excluded. The Gram stain
should not be performed in lieu of obtaining speci-
mens for the isolation of N. gonorrhoeae, C. tra-
chomatis, or other indicated STDs. A pap smear
should be obtained if several months have elapsed
since the patient’s last pap smear or if she has evi-
dence of cervicitis. The pap smear will help to
establish the presence of an inflammatory condition
or, if all culture data are negative, a viral infection.
In addition to cultures for N. gonorrhoeae and C.
trachomat#, specimens should be obtained for M.
hominis and U. urealyticum.
Next, a bimanual examination should be per-
formed. Although the patient may be suspected of
having an uncomplicated lower genital tract infec-
tion, it is crucial to the preservation of her fertility
and prevention of an ectopic pregnancy that upper
genital tract involvement be ruled out. The presen-
tation of a patient with pelvic inflammatory disease
(PID) is subtle, in contrast to the presentation of an
individual with obvious salpingitis, who has a pu-
rulent discharge, cervical motion and adnexal ten-
derness, fever, and an elevated WBC count. The













derness on motion or palpation ofthe cervix, uterus,
or adnexa. Even though the patient is afebrile with
a normal WBC count, she may have vague lower
abdominal pain that she does not relate to the physi-
cian or is not aware of until a pelvic examination is
performed.
TREATMENT
As mentioned previously, the CDC’s recommenda-
tion for patients with suspected or proven uncom-
plicated gonococcal or chlamydial infection is the
administration of ceftriaxone, 250 mg IM, fol-
lowed by doxycycline, 100 gm orally twice daily
for 7 days.
14 However, this treatment is costly and
time-consuming, and the IM injection may be pain-
ful to the patient. The new quinolone ofloxacin
offers the opportunity to treat both gonococcal and
chlamydial infections with a single oral agent.
The fluoroquinolones are derived from nalidixic
acid, which was placed in clinical use in 1962 pri-
marily for the treatment of gram-negative urinary
traction infections.
16 The new quinolones differ
from nalidixic acid in having a fluorine atom and
piperazyl moiety (Table 3). Although the fluoro-
quinolones all possess the basic quinolone struc-
turea fluorine atom at the 6 position and a piper-
azine ring at the 7 positionmthey differ from one
another by substitutions at the position. Ofloxacin
is unique among the fluoroquinolones in that it has
a tricyclic ring structure. The tricyclic ring results
in the molecule’s having increased gram-positive
and anaerobic activity and decreased metabolism.
Ofloxacin has a broad spectrum of activity that
includes gram-positive aerobic and facultative
anaerobes (Table 4). Bacteroidesfragilis, Bacteroides
melaninogenicus, Fusobacterium, Peptostreptococcus,
and Clostridium difficile are all sensitive to ofloxa-
cin.
17-20 However, its efficacy in the treatment of
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blncludes both penicillin-sensitive and penicillin-resistant strains.
infections involving anaerobic bacteria has not been
established. Until sufficient data are available, an
agent with a proven anaerobic spectrum should be
included in the treatment regimen.
The antimicrobial spectrum of activity exhibited
by ofloxacin makes it useful for a variety of infec-
tions, e.g., skin and soft tissue, respiratory, uri-
nary tract, gonococcal, and chlamydial infec-
tions.
21-24 The susceptible minimal inhibitory
concentration (MIC) breakpoint is 2 Ixg/ml, and
the MIC for resistance is > 8 g/ml. 25’26 In vitro
and in vivo studies have shown that ofloxacin is as
effective as amoxicillin or ampicillin plus probene-
cid and doxycycline for the treatment of gonococcal
and chlamydial infection. In a multicenter study, a
single 400-mg dose of ofloxacin was compared with
a single 3.0-g dose of amoxicillin or a 4.5-g dose of
ampicillin plus g of probenecid. Ofloxacin erad-
icated the gonococcus in 98% of the patients,
whereas the amoxicillin-probenecid regimen eradi-
cated 95%.
24 In a comparative study of the treat-
ment of chlamydia, 533 patients were randomly
assigned to a 7-day course of either ofloxacin, 300
mg every 12 hours, or doxycycline, 100 mg every
12 hours. The two agents were reported to be
equally effective, achieving cure rates of 99% and
95%, respectively.
27-3
Although ciprofloxacin has been shown to have
activity against N. gonorrhoeae and C. trachomatis,
patients treated for the latter have relapsed. There-
fore, while ciprofloxacin appears to be quite ade-
quate for the treatment of N. gonorrhoeae, it is not
reliable for the treatment of C. trachomatis. Nor-
floxacin also has activity against N. gonorrhoeae but
not against C. trachomatis. The use of norfloxacin
to treat cervical infection caused by N. gonorrhoeae
is appropriate but requires the addition of an agent
effective against C. trachomatis. To be cost-effec-
tive and therapeutically sound, the treatment of
cervicitis suspected of being caused by either or
both of these sexually transmitted bacteria should
be accomplished with a single effective agent such
as ofloxacin.
METABOLISM
Ofloxacin, unlike other fluoroquinolones, is not
metabolized to compounds with lesser antimicro-
bial activity. All fluoroquinolones except ofloxacin
are metabolized or produce an oxoquinolone me-
tabolite that interferes with the metabolism of theo-
phylline and caffeine.
31,2 Urinary recovery ofme-
tabolites of ofloxacin accounts for approximately
5% of the drug. The dosage of ofloxacin must be
adjusted in the face of renal impairment, that is, a
creatinine clearance of < 50 ml/min. The half-life
of ofloxacin is 9 hours. After the administration
of 500 mg of ofloxacin twice a day and achievement
of a plasma steady state, the peak level exceeding 5
Ixg/ml and trough level of p.g/ml are obtained.
TOXICITY
Approximately 3,200 patients in clinical trials in
the United States have received ofloxacin for 3 to
10 days. The most frequent adverse reactions were
nausea (3.5%), insomnia (1.8%), headache (1.4%),
and dizziness ( 1.2%).
Animal studies revealed that arthropathy, char-
acterized by blisters, erosion, and an increase in
synovial fluid, occurred in rats and dogs. The ef-
fects were age and dose dependent.
4 These effects
are characteristics of all quinolones and, although
arthropathy has not been demonstrated in humans,
children and pregnant women should not receive
fluoroquinolone therapy.
CONCLUSIONS
Of the quinolones currently available, only ofloxa-
cin presents the physician with the opportunity of
treating the two most common sexually transmitted
bacterial infections with a single agent. The CDC
recommended in 1985 that any treatment for un-
complicated gonorrhea include treatment for
chlamydial infection.
14 This recommendation was
deemed necessary because ofthe decrease in efficacy
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of penicillin in treating gonococcal infection and
the increase in the chromosomally mediated resis-
tance of N. gonorrhoeae to tetracycline as well as
penicillin.
15 Ofloxacin offers the benefits of not
being affected by enzymes that afford the gonococ-
cus resistance to tetracycline or penicillins and of
being effective as a single dose. The antibacterial
activity of the quinolones resides in their ability to
interfere with DNA synthesis by inhibiting the
bacterial DNA gyrase enzyme that is responsible
for the spiral structure producing supercoils, which
are characteristic of DNA. 3s’36 The fact that only
bacteria possess DNA gyrase increases the safety of
fluoroquinolones. Since ofloxacin is taken orally
and has excellent absorption via the gastrointestinal
tract, therapy is facilitated in busy clinical settings
in comparison with IM injection of ceftriaxone or 3
to 4.5 g of amoxicillin or ampicillin.
The spectrum of activity of ofloxacin makes this
agent potentially suited for the treatment of PID.
Initial studies (unpublished) have shown that oflox-
acin is as effective as cefoxitin in the treatment of
early, uncomplicated PID. The major concern is
the decreased activity of quinolones against gram-
negative obligate anaerobes. However, an individ-
ual experiencing a first episode ofPID is primarily
infected with N. gonorrhoeae, or C. trachomatis, or
both and is not likely to have a complex infection
involving both aerobic and anaerobic bacteria. If
there is a concern over a possible mixed aerobic and
anaerobic infection, ofloxacin, which provides ex-
cellent coverage against N. gonorrhoeae, C. tra-
chomatis, Enterobacteriaceae, and gram-positive
aerobic cocci, could be administered with an agent
such as metronidazole. Additional studies are
needed to determine if ofloxacin is indicated in the
treatment of PIE).
There is no doubt that ofloxacin is well suited for
the treatment of uncomplicated gonococcal and
chlamydial infection. Although ofloxacin has been
associated with low toxicity, arthropathic effects
have been demonstrated in rats and dogs. There-
fore, ofloxacin, like other quinolones, should not
be administered to children younger than 18 years
of age or to pregnant or breastfeeding women.
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